Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-022-02128-6
Abstract: This study aimed to analyze changes in the plasma concentration of EGFR-mutated circulating tumor DNA (ctDNA) occurring immediately after the start of therapy with EGFR tyrosine kinase inhibitors (TKIs). Serial plasma samples were collected from… read more here.
Keywords: egfr driven; patients egfr; egfr mutated; concentration egfr ... See more keywords
RBM10 loss promotes EGFR-driven lung cancer and confers sensitivity to spliceosome inhibition.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer research"
DOI: 10.1158/0008-5472.can-22-1549
Abstract: In lung adenocarcinoma (LUAD), loss-of-function mutations in the splicing factor RBM10 frequently co-occur with oncogenic EGFR mutations. A detailed understanding of the functional consequences and therapeutic impact of RBM10 loss in EGFR-mutant LUAD could help… read more here.
Keywords: rbm10 loss; egfr driven; loss; lung ... See more keywords
Abstract 2545: NNMT is a novel effector of EGFR driven glioblastoma malignancy
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2545
Abstract: Nicotinamide N-methyltransferase (NNMT) is a metabolic enzyme that catalyzes the conversion of methyl groups from S-adenosyl-L-methionine (SAM) to nicotinamide (NAM) to generate S-adenosine hyperblastoids (SAH) and 1-methylnicotinamide (MNA). Upregulation of NNMT has been observed in… read more here.
Keywords: glioblastoma; driven glioblastoma; nnmt novel; egfr driven ... See more keywords
Abstract A34: Understanding mechanisms of checkpoint blockade in EGFR-driven glioblastoma
Sign Up to like & getrecommendations! Published in 2018 at "Cancer immunology research"
DOI: 10.1158/2326-6074.tumimm17-a34
Abstract: Background and Rationale: Glioblastoma multiforme (GBM) is the most common type of malignant glioma and has a poor prognosis, which calls for the exploration of alternative therapeutic approaches. Checkpoint blockade immunotherapies have produced significant clinical… read more here.
Keywords: checkpoint blockade; combination; egfr driven; blockade ... See more keywords
EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14163943
Abstract: Simple Summary Lung cancer that is driven by mutations in the epidermal growth factor receptor (EGFR) is currently treated with tyrosine kinase inhibitors (TKIs). Although patients initially respond well to TKI treatment, drug resistance against… read more here.
Keywords: egfr driven; egfr inhibition; egfr; immune ... See more keywords
cyy-287, a novel pyrimidine-2,4-diamine derivative, inhibits tumor growth of EGFR-driven non-small cell lung cancer via the ERK pathway
Sign Up to like & getrecommendations! Published in 2022 at "Acta Biochimica et Biophysica Sinica"
DOI: 10.3724/abbs.2022139
Abstract: In recent decades, EGFR-targeted tyrosine kinase inhibitors (TKIs) have been proven to be an effective therapy for EGFR-mutant non-small cell lung cancer (NSCLC). However, resistance to EGFR-TKIs limits their clinical application. In the present study,… read more here.
Keywords: erk pathway; cyy 287; non small; egfr driven ... See more keywords